Posted by Michael Wonder on 24 Mar 2020
Prevail Therapeutics receives U.S. FDA fast track designation for PR006 to slow the progression of frontotemporal dementia with a GRN mutation
24 March 2020 - Prevail Therapeutics today announced that the U.S. FDA has granted fast track designation for the Company’s experimental gene therapy program, PR006, to slow the progression of fronto-temporal dementia with a GRN mutation.
Prevail announced an active IND for the Phase 1/2 clinical trial of PR006 for the treatment of frontotemporal dementia with a GRN mutation earlier this month.
